Prevalence of severe side effects in the PACE-B trial

Alison Tree, BSc, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, discusses survivorship in the PACE-B trial (NCT01584258) comparing hypofractionated stereotactic body radiotherapy (SBRT) to conventional radiotherapy for treating men with localised prostate cancer. The trial results show that less than 1% of patients experienced severe side effects two years after treatment, regardless of which treatment group they were assigned. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2021.